In January 2025, several companies announced collaborations with international pharmaceutical giants to launch a series of new drugs globally.

In January 2025, a series of collaborative agreements were successively reached in the field of antibody-based pharmaceuticals in China.

In January 2025, China’s innovative pharmaceutical sector continues to make its mark on the global stage.

Sarcopenia, a condition characterized by age - related muscle loss and strength decline, is a growing health concern.

Beyond the drugs targeting specific pathways like the Activin - ActRII - ActRI pathway, there are other medications being developed for obesity and muscle - wasting disorders.

The discovery of INHBE and ALK7 as potential drug targets has opened up new avenues in the development of therapies for obesity and metabolic disorders.

By conducting in - depth searches in relevant databases, the development of drugs targeting MSTN/GDF8 and bone morphogenetic proteins (BMPs) has been revealed.

Through comprehensive searches in the Patsnap Synapse database, it has been found that the key drugs targeting ActRII mainly consist of fusion proteins and monoclonal antibodies.

In the pursuit of treating muscle - related diseases and achieving effective weight management with the goal of “fat loss with muscle gain”.

The Activin - ActRII - ActRI pathway plays a vital role in cell growth and differentiation, and understanding its mechanism of action is essential.

In January 2025, several significant mergers and acquisitions (M&A) took place in the biopharmaceutical industry.

The Activin - ActRII - ActRI pathway is a key regulatory pathway in muscle growth and has attracted significant attention in the research of muscle - related diseases and weight - loss therapies.